Cargando…

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm(3) and/or previous AIDS) receiving the third do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vergori, Alessandra, Cozzi Lepri, Alessandro, Cicalini, Stefania, Matusali, Giulia, Bordoni, Veronica, Lanini, Simone, Meschi, Silvia, Iannazzo, Roberta, Mazzotta, Valentina, Colavita, Francesca, Mastrorosa, Ilaria, Cimini, Eleonora, Mariotti, Davide, De Pascale, Lydia, Marani, Alessandra, Gallì, Paola, Garbuglia, AnnaRosa, Castilletti, Concetta, Puro, Vincenzo, Agrati, Chiara, Girardi, Enrico, Vaia, Francesco, Antinori, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395398/ https://www.ncbi.nlm.nih.gov/pubmed/35995780 http://dx.doi.org/10.1038/s41467-022-32263-7

Ejemplares similares

Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
por: Antinori, Andrea, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH
por: Vergori, Alessandra, et al.
Publicado: (2022)

Neutralizing activity and T Cell response after bivalent fifth dose of mRNA vaccine in person living with HIV
por: Vergori, Alessandra, et al.
Publicado: (2023)

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
por: Mazzotta, Valentina, et al.
Publicado: (2022)

Viral load decrease in SARS‐CoV‐2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents
por: Valentina, Mazzotta, et al.
Publicado: (2022)

SARS-CoV-2 Specific Immune Response and Inflammatory Profile in Advanced HIV-Infected Persons during a COVID-19 Outbreak
por: Vergori, Alessandra, et al.
Publicado: (2022)

Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH
por: Gagliardini, Roberta, et al.
Publicado: (2022)

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
por: Agrati, Chiara, et al.
Publicado: (2022)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
por: Agrati, Chiara, et al.
Publicado: (2021)

SARS-CoV-2 Infection of Airway Epithelium Triggers Pulmonary Endothelial Cell Activation and Senescence Associated with Type I IFN Production
por: Bordoni, Veronica, et al.
Publicado: (2022)

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
por: Agrati, Chiara, et al.
Publicado: (2021)

Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy
por: Colavita, Francesca, et al.
Publicado: (2022)

SARS-CoV-2 nasopharyngeal viral load in individuals infected with BA.2, compared to Alpha, Gamma, Delta and BA.1 variants: A single-center comparative analysis
por: Mastrorosa, Ilaria, et al.
Publicado: (2022)

T helper profile in pregnant women recovered from COVID-19
por: Tartaglia, Eleonora, et al.
Publicado: (2022)

Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
por: Agrati, Chiara, et al.
Publicado: (2022)

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
por: Puro, Vincenzo, et al.
Publicado: (2021)

Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia
por: Vergori, Alessandra, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
por: Agrati, Chiara, et al.
Publicado: (2021)

Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up
por: Matusali, Giulia, et al.
Publicado: (2022)

The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals
por: Bordoni, Veronica, et al.
Publicado: (2022)

Asymptomatic Mpox Virus Infection in Subjects Presenting for MVA-BN Vaccine
por: Matusali, Giulia, et al.
Publicado: (2023)

No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison
por: Gagliardini, Roberta, et al.
Publicado: (2021)

Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature
por: Fabbri, Gabriele, et al.
Publicado: (2017)

Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test
por: Meschi, Silvia, et al.
Publicado: (2020)

Vδ2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity
por: Cimini, Eleonora, et al.
Publicado: (2019)

Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding
por: Lapa, Daniele, et al.
Publicado: (2022)

Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022
por: Antinori, Andrea, et al.
Publicado: (2022)

What is the impact of post-COVID-19 syndrome on health-related quality of life and associated factors: a cross-sectional analysis
por: Mastrorosa, Ilaria, et al.
Publicado: (2023)

Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination
por: Matusali, Giulia, et al.
Publicado: (2023)

Comparison of SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples from Patients Infected with Omicron Variant
por: Bordi, Licia, et al.
Publicado: (2023)

SARS-CoV-2 infection does not induce HIV viral escape in the central nervous system: A case series
por: Pinnetti, C., et al.
Publicado: (2020)

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
por: Tortorella, Carla, et al.
Publicado: (2022)

SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel
por: Santoro, Annapaola, et al.
Publicado: (2023)

SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus
por: Matusali, Giulia, et al.
Publicado: (2021)

Cellular and Humoral Cross-Immunity against Two H3N2v Influenza Strains in Presumably Unexposed Healthy and HIV-Infected Subjects
por: Agrati, Chiara, et al.
Publicado: (2014)

Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals
por: Rozera, Gabriella, et al.
Publicado: (2017)

Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV
por: Pinnetti, Carmela, et al.
Publicado: (2022)

Evaluating the Dual-Target Aptima HIV-1 Quant Dx Assay: Comparison between Viral Loads Measured with pol and LTR Targets in the Same Samples
por: Sberna, Giuseppe, et al.
Publicado: (2022)

Results of an interventional HIV testing programme in the context of a mpox (formerly monkeypox) vaccination campaign in Latium Region, Italy, August to October 2022
por: Pittalis, Silvia, et al.
Publicado: (2022)

Tropism of the Chikungunya Virus
por: Matusali, Giulia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dh133982okibdbl6u3qns4n3r2